Telix announced completion of patient enrollment in the Phase 1 IPAX-2 trial of TLX101-Tx for newly diagnosed glioblastoma, with no dose-limiting toxicities observed including at the maximum dose. This de-risks the safety profile of TLX101-Tx as it advances alongside the pivotal Phase 3 IPAX BrIGHT trial in recurrent GBM, but the readout is early-stage safety data with no efficacy results.
Price Chart
Executive Summary
Telix announced completion of patient enrollment in the Phase 1 IPAX-2 trial of TLX101-Tx for newly diagnosed glioblastoma, with no dose-limiting toxicities observed including at the maximum dose. This de-risks the safety profile of TLX101-Tx as it advances alongside the pivotal Phase 3 IPAX BrIGHT trial in recurrent GBM, but the readout is early-stage safety data with no efficacy results.
Key Facts
- IPAX-2 Phase 1 study (TLX101-Tx in newly diagnosed GBM) completed enrollment of 12 patients across 3 cohorts.
- No dose-limiting toxicities (DLTs) observed, including at the maximum administered dose of 10 GBq (two 5 GBq doses).
- ,
- ],
Financial Impact
Not specified
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3297047 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $12.83 $11.95 | ▼ −6.86% | ▼ −8.99% | $10.55 (−17.77%) |
Sep 14, 2026 18d ago | Press Release | $11.78 $11.31 | ▼ −3.99% | ▼ −4.10% | $10.55 (−10.44%) |
Sep 2, 2026 4w ago | 6-K | $11.45 $11.90 | ▲ +3.93% | ▲ +4.89% | $10.55 (−7.86%) |
Sep 1, 2026 4w ago | Press Release | $11.45 $11.90 | ▲ +3.93% | ▲ +4.89% | $10.55 (−7.86%) |
Aug 20, 2026 6w ago | 6-K | $12.42 $11.38 | ▼ −8.41% | ▼ −9.53% | $10.55 (−15.06%) |
Aug 20, 2026 6w ago | Press Release | $12.42 $11.38 | ▼ −8.41% | ▼ −9.53% | $10.55 (−15.06%) |
Jul 30, 2026 9w ago | Press Release | $9.89 $11.52 | ▲ +16.48% | ▲ +12.97% | $10.55 (+6.67%) |
Jul 21, 2026 10w ago | Press Release | $10.32 $10.10 | ▼ −2.13% | ▲ +0.27% | $10.55 (+2.23%) |
Jul 21, 2026 10w ago | 6-K | $10.92 $9.98 | ▼ −8.61% | ▼ −7.38% | $10.55 (−3.39%) |
Jul 20, 2026 10w ago | Press Release | $10.92 $9.98 | ▼ −8.61% | ▼ −7.38% | $10.55 (−3.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access